Identification and characterization of p100HB, a new mutant form of p100/NF-kappa B2.

Biochem Biophys Res Commun

Oncogenèse, Différenciation et Transduction du Signal, UPR 9079 du CNRS, Institut André Lwoff,7, rue Guy Môquet, 94801 Villejuif, France.

Published: September 2003

P100, which is encoded by NF-kappa B2, inhibits Rel dimers. It can also be processed into p52, one of the DNA binding sub-units of NF-kappa B/Rel factors. Several p100 C-terminal truncations that result from gene rearrangements are associated with lymphomagenesis. Here, we characterized a new p100 mutant that we termed p100HB. It originates from a point-mutation that generates a premature stop-codon, and thus the protein lacks the last 125 amino acids. We have detected p100HB in several human tumor cell lines. The truncated protein is mainly unprocessed, and although it still binds Rel dimers, it has reduced inhibitory potency compared to p100 and translocates into the nucleus. Thus, p100HB may be associated with deregulated NF-kappa B/Rel functions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-291x(03)01474-8DOI Listing

Publication Analysis

Top Keywords

rel dimers
8
nf-kappa b/rel
8
identification characterization
4
p100hb
4
characterization p100hb
4
p100hb mutant
4
mutant form
4
form p100/nf-kappa
4
p100
4
p100/nf-kappa p100
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!